EP1027049A4 - Intranasale formulierung enthaltend scopolamin und verfahren zur behandlung von reisekrankheit - Google Patents

Intranasale formulierung enthaltend scopolamin und verfahren zur behandlung von reisekrankheit

Info

Publication number
EP1027049A4
EP1027049A4 EP98946945A EP98946945A EP1027049A4 EP 1027049 A4 EP1027049 A4 EP 1027049A4 EP 98946945 A EP98946945 A EP 98946945A EP 98946945 A EP98946945 A EP 98946945A EP 1027049 A4 EP1027049 A4 EP 1027049A4
Authority
EP
European Patent Office
Prior art keywords
formulation containing
motion sickness
intranasal formulation
treating motion
containing scopolamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP98946945A
Other languages
English (en)
French (fr)
Other versions
EP1027049A1 (de
Inventor
Raja G Achari
Charanjit R Behl
Prafulla K Chowhan
Meireles C Jorge De
Ramneik Dua
Vincent D Romeo
Anthony P Sileno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marina Biotech Inc
Original Assignee
MDRNA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MDRNA Inc filed Critical MDRNA Inc
Publication of EP1027049A1 publication Critical patent/EP1027049A1/de
Publication of EP1027049A4 publication Critical patent/EP1027049A4/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP98946945A 1997-09-11 1998-09-11 Intranasale formulierung enthaltend scopolamin und verfahren zur behandlung von reisekrankheit Ceased EP1027049A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5865197P 1997-09-11 1997-09-11
US58651P 1997-09-11
PCT/US1998/018953 WO1999012544A1 (en) 1997-09-11 1998-09-11 Intranasal formulation containing scopolamine and method of treating motion sickness

Publications (2)

Publication Number Publication Date
EP1027049A1 EP1027049A1 (de) 2000-08-16
EP1027049A4 true EP1027049A4 (de) 2001-09-05

Family

ID=22018094

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98946945A Ceased EP1027049A4 (de) 1997-09-11 1998-09-11 Intranasale formulierung enthaltend scopolamin und verfahren zur behandlung von reisekrankheit

Country Status (5)

Country Link
EP (1) EP1027049A4 (de)
JP (1) JP2002516815A (de)
AU (1) AU742878B2 (de)
CA (1) CA2303132C (de)
WO (1) WO1999012544A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024116A1 (en) * 2000-09-20 2002-03-28 Shahinian, Lee, Jr. Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
EP2006289B1 (de) 2006-03-31 2011-11-30 Wako Pure Chemical Industries, Ltd. Cyaninfarbstoff vom pyrazoltyp
ATE553221T1 (de) 2007-01-31 2012-04-15 Wako Pure Chem Ind Ltd Verfahren zum nachweis von amplifikation oder deletion in einem genomischen dna-fragment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0131315A2 (de) * 1983-05-13 1985-01-16 ISTITUTO DE ANGELI S.p.A. Nasalpräparate mit anticholinergischen Quaternärammoniumsalzen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7765615B2 (en) * 2007-03-28 2010-08-03 Michael Robert Eastwood Chest protector in sports medicine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0131315A2 (de) * 1983-05-13 1985-01-16 ISTITUTO DE ANGELI S.p.A. Nasalpräparate mit anticholinergischen Quaternärammoniumsalzen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PUTCHA LAKSHIMI ET AL: "Bioavailability of intranasal scopolamine in normal subjects.", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 85, no. 8, 1996, pages 899 - 902, XP002171369, ISSN: 0022-3549 *
See also references of WO9912544A1 *

Also Published As

Publication number Publication date
AU742878B2 (en) 2002-01-17
CA2303132C (en) 2002-07-09
JP2002516815A (ja) 2002-06-11
CA2303132A1 (en) 1999-03-18
EP1027049A1 (de) 2000-08-16
WO1999012544A1 (en) 1999-03-18
AU9385098A (en) 1999-03-29

Similar Documents

Publication Publication Date Title
AP2000001783A0 (en) Disinfectant and method of making
GB2334444B (en) Hair treatment composition and method of manufacturing the composition
PL331863A1 (en) 7alpha-(xi-aminoalkyl)-estrathienes, method of obtaining them, pharmacautic preparations containing such compounds and their application in production of therapeutic agents
PL322624A1 (en) Skin care composition containing retinoides and liposomes
PL334678A1 (en) Quinolinic and quinazolinic compounds useful in therapy in particular in that of bph
PL337999A1 (en) Hair direct dyeing compositions containing novel mixtures of antraquinones and method of dyeing human hair
GB9715508D0 (en) Industrial fabrics and method of treatment
US5656608B1 (en) Amino acid compositions and methods of treatment using same
ZA9610901B (en) Treatment and prophylaxis of osteoporosis
EP0975654A4 (de) Zubereitung und verfahren zur behandlung von cmv-infektionen
ZA964562B (en) Antipsychotic agents compositions and method of use
EP1027049A4 (de) Intranasale formulierung enthaltend scopolamin und verfahren zur behandlung von reisekrankheit
EP1009433A4 (de) Therapeutische zusammensetzung und verfahren zur behandlung
GB2277681B (en) Hair treatment device and method
HUP0002981A3 (en) Abrasive cleaning composition and method of cleaning
PL303822A1 (en) Therapeutic compositions containing ipsapyrone and method of obtaining them
IL112257A0 (en) Treatment of motion sickness
CZ362797A3 (cs) Způsob zpracování pojiv a jejich použití
EP1015559A4 (de) Serpin-1 (rasp-1), einhergehend mit regenerierung, sowie anwendungsverfahren
EP0963968A4 (de) Mittel und verfahren zur oberflächen behandlung von anorganischen teilen auf kalzium basis
ZA969563B (en) Cleaning concentrates and method of preparation
GB2326704B (en) Processing apparatus and method of use
GB9707163D0 (en) Cleaning composition and method of use
GB9706608D0 (en) Decontamination and treatment of metal surfaces
IL109504A0 (en) Scalp treatment composition and cosmetic treatment for scalp

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000329

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010724

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020103

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NASTECH PHARMACEUTICAL COMPANY, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20051102